Imetelstat is a telomerase inhibitor and a synthetic oligonucleotide-based pharmaceutical compound designed to inhibit the activity of telomerase, an enzyme that plays an important role in maintaining telomere length in rapidly dividing cells.
Imetelstat is primarily associated with the treatment of myelofibrosis and myelodysplastic syndromes (MDS) in specific patient populations. It represents a targeted therapeutic approach involving inhibition of telomerase activity in malignant hematopoietic cells.
Imetelstat is a specialized oligonucleotide-based pharmaceutical active ingredient requiring sophisticated manufacturing, purification and analytical characterization. Unlike conventional small-molecule APIs, its quality assessment requires characterization of the oligonucleotide sequence, purity, identity and biological activity.
Important quality attributes may include full-length product content, sequence identity, related oligonucleotide impurities, truncated sequences, residual solvents, water content, counter-ion content and endotoxin levels, depending on the manufacturing stage and specification.
CAS Number: 868169-20-6
Molecular Formula: C204H336N67O120P20
Molecular Weight: Approximately 6581.2 g/mol
Molecule Type: Oligonucleotide / Telomerase Inhibitor
Drug Class: Antineoplastic Agent
Pharmacological Class: Telomerase Inhibitor
Therapeutic Class: Anticancer Agent
Therapeutic Area: Oncology / Hematology
Imetelstat is designed to bind to the RNA template component of human telomerase.
Telomerase enables certain cells to maintain telomere length, supporting continued cellular division. Malignant stem and progenitor cells can rely on telomerase activity for long-term proliferation.
By binding to the telomerase RNA template, Imetelstat inhibits telomerase enzymatic activity. Continued inhibition can result in telomere shortening and reduced proliferative capacity of susceptible malignant cells.
Imetelstat is used in approved pharmaceutical applications for selected patients with:
The exact indication depends on the approved regulatory labeling and treatment setting.
Imetelstat provides a therapeutic approach that differs from conventional kinase inhibitors and cytotoxic chemotherapy by targeting telomerase activity.
Telomerase inhibition is particularly relevant to research into malignant hematopoietic stem and progenitor cells, where sustained telomerase activity can contribute to cellular immortality.
Imetelstat is an oligonucleotide-based therapeutic. Its development requires specialized manufacturing and characterization techniques suitable for complex nucleic-acid-based pharmaceutical substances.
Compared with conventional chemical APIs, oligonucleotide APIs require additional controls for:
Production of Imetelstat involves specialized oligonucleotide synthesis and purification technology. Depending on the manufacturing platform, key stages may include:
Each stage requires appropriate process controls to ensure consistent oligonucleotide quality.
Imetelstat quality evaluation may include:
Imetelstat should be stored according to validated stability data and the applicable pharmaceutical specification. Oligonucleotide drug substances and products generally require controlled environmental conditions and protection from unsuitable temperature, moisture and light exposure.
Imetelstat is relevant to pharmaceutical research involving:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |